Notice of Intent to Sole Source - The Children's Hospital Corporation -
Closed Special Notice Posted
- Solicitation number
- 2024-87883
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- Atlanta, Georgia 30341, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services, Centers for Disease Control and Prevention, Office of Acquisition Services has issued a Special Notice to evaluate the protection attributed to nirsevimab and maternal RSV vaccine receipt against severe RSV disease. The agency is seeking a contractor to leverage the existing infrastructure of the Overcoming COVID-19 Study Network and the existing protocol to evaluate the effectiveness of these products against severe RSV disease in infants and against any RSV hospitalization in the second year of life, as well as assess RSV clinical progression among ICU-admitted infants by product receipt status.
The purpose of this effort is to representatively enroll case-infants hospitalized with RSV and suitable matched controls to fulfill the specific objectives. The Special Notice has a due date of August 29, 2024, and the work falls under the NAICS code 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and the PSC code AN41 - Health R&D Services; Health Care - Other; Basic Research. There is no set-aside requirement, and the agency is looking to sole source the requirement to The Children's Hospital Corporation.
Notice text
- In this Task, the Contractor shall evaluate protection attributed to nirsevimab and maternal RSV vaccine receipt against severe RSV by leveraging representative enrollment of patients hospitalized with RSV and suitable matched controls as noted below. The Contractor shall use the existing infrastructure of the Overcoming COVID-19 Study Network and leverage the existing protocol. The specific objectives related to RSV product effectiveness are to: 1) Evaluate effectiveness of nirsevimab and maternal RSV vaccination against severe RSV disease in infants and against any RSV hospitalization in the 2nd year of life, by product, and assess duration of protection; and 2) Assess RSV clinical progression among ICU-admitted infants by nirsevimab or maternal vaccination receipt status within predetermined age groups. In performing this Task, the Contractor shall:
- Representatively enroll case-infants <2 years of age admitted to the intensive care unit (ICU) or step-down unit (SDU) with severe RSV disease. Target enrollment goals for RSV product/vaccine effectiveness cases and controls with respiratory viral LRTI is approximately 1500-1600 patients <12 months of age in each group, and approximately 1200-1300 representatively enrolled patients between 8 months and 2 years of age who were hospitalized in either the ward or ICU.
- Consecutively enroll RSV patients to facilitate enrollment for product effectiveness investigations while utilizing existing resources specified in the core tasks. SARS-CoV-2-positive and RSV-positive case-patients may share the same non-COVID-19, non-RSV ARI control, although RSV VE controls shall be matched to RSV case-patients by level of care (e.g., ICU vs ward admissions) in addition to site, age group, and time of admission, as specified in the core task.
- Among enrolled patients for this Task, collect detailed information on clinical severity and course, including mechanical ventilation, oxygenation index, duration of respiratory support, and extracorporeal membrane oxygenation support. Maternal vaccination status or infant nirsevimab receipt status must be verified through a combination of any of the following: hospital EMR (from the birth hospital if records cannot be verified at treating hospital), state IIS (registry) of patient’s state of residence; pediatrician records; mother’s prenatal medical records; or pharmacy, or other CDC-approved sources of verification determined on a case-by-case basis.
- Collect and submit newly drawn or discarded blood/sera samples to assess immune response in RSV cases and controls.
- Revise the existing Protocol, Forms, and Data Dictionary to incorporate the activities of this Task.
- Include enrollment and progress in Biweekly Enrollment and Quarterly Summary Reports as due for the Surveillance and VE Evaluation.
- The Contractor will ship blood specimens periodically, but no less than quarterly, to CDC or CDC-Designated Laboratory.
- Provide Monthly Interim Datasets and Final Dataset.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity